152 related articles for article (PubMed ID: 9074912)
21. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A
Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176
[TBL] [Abstract][Full Text] [Related]
22. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
23. Terguride in stable Parkinson's disease.
Martignoni E; Pacchetti C; Aufdembrinke B; Godi L; Albani G; Mancini F; Nappi G
Funct Neurol; 1995; 10(3):143-6. PubMed ID: 8557216
[TBL] [Abstract][Full Text] [Related]
24. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular adaptation to orthostatic stress during vasodilator therapy.
Lipsitz LA; Connelly CM; Kelley-Gagnon M; Kiely DK; Abernethy D; Waksmonski C
Clin Pharmacol Ther; 1996 Oct; 60(4):461-71. PubMed ID: 8873694
[TBL] [Abstract][Full Text] [Related]
26. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease.
Laihinen A; Rinne UK; Suchy I
Acta Neurol Scand; 1992 Dec; 86(6):593-5. PubMed ID: 1481646
[TBL] [Abstract][Full Text] [Related]
27. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
28. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
29. The hemodynamic effects of triglycyl-lysine-vasopressin (Glypressin) in patients with parkinsonism and orthostatic hypotension.
Rittig S; Arentsen J; Sørensen K; Matthiesen T; Dupont E
Mov Disord; 1991; 6(1):21-8. PubMed ID: 2005918
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease.
Capria A; Attanasio A; Quatrana M; Cannata D; Fioravanti M; Stocchi F; Ruggieri S
Clin Neuropharmacol; 1989 Aug; 12(4):331-8. PubMed ID: 2804995
[TBL] [Abstract][Full Text] [Related]
31. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Stryjer R; Klein C; Treves TA; Rabey JM
Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
[TBL] [Abstract][Full Text] [Related]
32. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
33. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
[TBL] [Abstract][Full Text] [Related]
34. Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study.
Battistin L; Bardin PG; Ferro-Milone F; Ravenna C; Toso V; Reboldi G
Acta Neurol Scand; 1999 Jan; 99(1):36-42. PubMed ID: 9925236
[TBL] [Abstract][Full Text] [Related]
35. The dopamine transporter: importance in Parkinson's disease.
Nutt JG; Carter JH; Sexton GJ
Ann Neurol; 2004 Jun; 55(6):766-73. PubMed ID: 15174010
[TBL] [Abstract][Full Text] [Related]
36. Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement.
Lucetti C; Gambaccini G; Del Dotto P; Ceravolo R; Logi C; Rossi G; Murri L; Bonuccelli U
Parkinsonism Relat Disord; 2006 Jun; 12(5):279-83. PubMed ID: 16549382
[TBL] [Abstract][Full Text] [Related]
37. [Letter: Effect of bromocryptine on the fluctuations following dopa therapy. On-off phenomenon in parkinsonian patients].
Frattola L; Albizzati MG; Spano PF; Trabucchi M
Nouv Presse Med; 1976 Aug 28-Sep 4; 5(28):1761. PubMed ID: 958891
[No Abstract] [Full Text] [Related]
38. Selegiline and blood pressure in patients with Parkinson's disease.
Pursiainen V; Korpelainen TJ; Haapaniemi HT; Sotaniemi AK; Myllylä VV
Acta Neurol Scand; 2007 Feb; 115(2):104-8. PubMed ID: 17212613
[TBL] [Abstract][Full Text] [Related]
39. Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction.
Holmberg B; Corneliusson O; Elam M
Mov Disord; 2005 Aug; 20(8):976-81. PubMed ID: 15858814
[TBL] [Abstract][Full Text] [Related]
40. Cardiopressor effects of short-term treatment with cabergoline in L-dopa stable responder parkinsonian patients: relevance of postprandial hypotension.
Cavallini A; Micieli G; Martignoni E; Blandini F; Fariello R; Nappi G
Clin Neuropharmacol; 1991 Aug; 14(4):343-51. PubMed ID: 1680557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
